Request Your Free White Paper Now:

"Maximizing Real-World Survival: Biomarker Testing in NSCLC"

Discover how biomarker testing and targeted therapies are reshaping survival outcomes in metastatic NSCLC.

Unlock critical insights to help pharma market access teams drive better outcomes in metastatic non-small cell lung cancer (NSCLC). This whitepaper leverages real-world data to highlight the transformative role of biomarker testing and targeted therapies in improving survival rates.

What’s inside:

• Evidence linking biomarker testing and therapy combinations to significantly extended survival.
• Real-world data on testing and treatment patterns across diverse patient populations.
• Analysis of demographic and socioeconomic factors influencing outcomes.
• Opportunities to address gaps in testing and ensure equitable access to life-extending therapies.
• With data from over 167,000 patients, this study provides actionable insights to help market access teams:
• Quantify unmet clinical needs and disparities in care.
• Inform value-based frameworks and reimbursement strategies.
• Support alignment with guideline-concordant care to improve patient outcomes.

This whitepaper is a must-read for market access professionals looking to optimize strategies, improve equity, and ensure timely access to biomarker-guided therapies.

Offered Free by: PurpleLab®
See All Resources from: PurpleLab®